Share Price and Basic Stock Data
Last Updated: January 24, 2026, 3:47 pm
| PEG Ratio | -2.99 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Chemfab Alkalis Ltd operates within the inorganic chemicals sector, primarily focusing on caustic soda and soda ash production. The company’s revenue has shown a steady upward trajectory, with reported sales of ₹331 Cr for the fiscal year ending March 2023, up from ₹272 Cr in the previous fiscal year. The trend continued with ₹327 Cr reported for March 2024, followed by ₹322 Cr for March 2025, indicating a slight decline but maintaining a strong sales base. Quarterly sales figures reflect this pattern, with ₹86.33 Cr recorded in December 2023, peaking at ₹87.85 Cr in March 2025. This indicates resilience despite fluctuations, particularly a dip to ₹73.30 Cr in March 2023. The company’s market capitalization stood at ₹564 Cr, with a share price of ₹389, which positions it favorably in the market, suggesting a sustained interest in its operational capabilities and growth potential.
Profitability and Efficiency Metrics
Chemfab Alkalis reported a net profit of ₹15 Cr for the fiscal year ended March 2023, which slightly decreased to ₹15 Cr in the subsequent year. The operating profit margin (OPM) has varied, achieving a high of 34% in March 2023 before declining to 17% in March 2025. This decline aligns with increasing operational costs, as expenses rose to ₹268 Cr in March 2025 from ₹219 Cr in March 2023. Efficiency metrics indicate a cash conversion cycle (CCC) of -12 days, showcasing effective working capital management and operational efficiency. The interest coverage ratio (ICR) reported at 10.32x suggests strong capacity to meet interest obligations, although the return on equity (ROE) and return on capital employed (ROCE) were lower at 3.69% and 5.89%, respectively, indicating challenges in generating returns relative to equity and capital employed in comparison to sector averages.
Balance Sheet Strength and Financial Ratios
The balance sheet of Chemfab Alkalis reflects a cautious approach towards debt, with total borrowings standing at ₹107 Cr against reserves of ₹399 Cr, resulting in a debt-to-equity ratio of 0.21. This conservative leverage provides a solid foundation for financial stability. The company reported a current ratio of 1.65, indicating adequate liquidity to cover short-term liabilities. The book value per share stood at ₹264.55, demonstrating a healthy asset base relative to liabilities. However, the price-to-book value ratio of 2.67x suggests that the stock is trading at a premium, which may raise concerns about valuation amidst declining profitability. The enterprise value (EV) to EBITDA ratio at 21.47x indicates that the market may be pricing in future growth potential, albeit with caution given the current financial performance.
Shareholding Pattern and Investor Confidence
The shareholding structure of Chemfab Alkalis is predominantly controlled by promoters, who hold 72.18% of the equity, reflecting strong internal confidence in the company’s strategies. Institutional investors have minimal engagement, with foreign institutional investors (FIIs) holding 0.00% and domestic institutional investors (DIIs) at 0.27%, indicating lower institutional interest. The public shareholding stands at 27.48%, which has shown a slight increase over the past quarters. The number of shareholders increased from 9,562 in December 2022 to 11,586 by September 2025, suggesting growing retail investor interest. However, the lack of significant institutional investment may signal caution among larger investors regarding the company’s growth trajectory and profitability challenges, which could impact future capital raising efforts.
Outlook, Risks, and Final Insight
Looking ahead, Chemfab Alkalis faces both opportunities and challenges. The company’s focus on expanding its product line and improving operational efficiencies could enhance profitability, especially if it manages to stabilize its expenses and improve margins. However, risks remain, including dependency on raw material prices and market competition, which could pressure margins further. Additionally, the low ROE and ROCE figures suggest that improving shareholder returns will be critical for long-term growth. If the company successfully navigates these risks while capitalizing on its market position, it could stabilize its financial performance. Conversely, failure to address profitability issues may result in a declining market sentiment, impacting share performance adversely. The company’s ability to leverage its reserves effectively will be crucial in determining its resilience in the face of these challenges.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Caprolactam Chemicals Ltd | 35.5 Cr. | 77.2 | 77.7/37.5 | 3,553 | 11.6 | 0.00 % | 0.48 % | 13.7 % | 10.0 |
| Standard Industries Ltd | 94.8 Cr. | 14.7 | 26.9/13.0 | 20.4 | 0.00 % | 7.81 % | 10.5 % | 5.00 | |
| Gujarat Alkalies & Chemicals Ltd | 3,333 Cr. | 454 | 710/443 | 22,218 | 759 | 3.48 % | 0.34 % | 1.13 % | 10.0 |
| GHCL Ltd | 4,843 Cr. | 527 | 779/511 | 8.50 | 378 | 2.28 % | 24.2 % | 18.6 % | 10.0 |
| Tata Chemicals Ltd | 18,177 Cr. | 714 | 1,027/692 | 55.8 | 877 | 1.54 % | 3.96 % | 1.20 % | 10.0 |
| Industry Average | 6,729.00 Cr | 363.15 | 5,174.60 | 389.00 | 1.27% | 7.11% | 8.14% | 9.17 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 76.01 | 83.94 | 73.30 | 79.08 | 79.58 | 86.33 | 82.30 | 76.04 | 79.00 | 79.21 | 87.85 | 87.58 | 70.41 |
| Expenses | 49.98 | 58.40 | 48.19 | 63.14 | 67.44 | 69.94 | 69.13 | 65.59 | 66.34 | 64.72 | 72.16 | 74.16 | 61.97 |
| Operating Profit | 26.03 | 25.54 | 25.11 | 15.94 | 12.14 | 16.39 | 13.17 | 10.45 | 12.66 | 14.49 | 15.69 | 13.42 | 8.44 |
| OPM % | 34.25% | 30.43% | 34.26% | 20.16% | 15.26% | 18.99% | 16.00% | 13.74% | 16.03% | 18.29% | 17.86% | 15.32% | 11.99% |
| Other Income | -2.25 | 2.10 | 1.45 | 3.58 | 1.19 | 1.25 | 1.76 | 2.57 | 0.59 | 1.42 | 1.27 | 1.06 | 1.35 |
| Interest | 0.04 | 0.04 | 0.04 | 0.04 | 0.06 | 0.43 | 0.41 | 0.51 | 1.22 | 1.63 | 1.56 | 1.56 | 1.92 |
| Depreciation | 5.85 | 5.71 | 5.44 | 5.39 | 5.59 | 5.40 | 5.47 | 6.41 | 7.82 | 8.51 | 9.64 | 5.38 | 5.60 |
| Profit before tax | 17.89 | 21.89 | 21.08 | 14.09 | 7.68 | 11.81 | 9.05 | 6.10 | 4.21 | 5.77 | 5.76 | 7.54 | 2.27 |
| Tax % | 26.05% | 28.32% | 24.86% | 29.67% | 30.34% | 30.91% | 27.40% | 29.18% | 29.93% | 30.16% | 31.77% | 28.38% | 29.96% |
| Net Profit | 13.23 | 15.68 | 15.84 | 9.91 | 5.35 | 8.16 | 6.56 | 4.33 | 2.95 | 4.02 | 3.93 | 5.39 | 1.59 |
| EPS in Rs | 9.36 | 11.09 | 11.17 | 6.98 | 3.77 | 5.74 | 4.61 | 3.03 | 2.06 | 2.81 | 2.74 | 3.75 | 1.11 |
Last Updated: January 2, 2026, 2:36 am
Below is a detailed analysis of the quarterly data for Chemfab Alkalis Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 70.41 Cr.. The value appears to be declining and may need further review. It has decreased from 87.58 Cr. (Jun 2025) to 70.41 Cr., marking a decrease of 17.17 Cr..
- For Expenses, as of Sep 2025, the value is 61.97 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 74.16 Cr. (Jun 2025) to 61.97 Cr., marking a decrease of 12.19 Cr..
- For Operating Profit, as of Sep 2025, the value is 8.44 Cr.. The value appears to be declining and may need further review. It has decreased from 13.42 Cr. (Jun 2025) to 8.44 Cr., marking a decrease of 4.98 Cr..
- For OPM %, as of Sep 2025, the value is 11.99%. The value appears to be declining and may need further review. It has decreased from 15.32% (Jun 2025) to 11.99%, marking a decrease of 3.33%.
- For Other Income, as of Sep 2025, the value is 1.35 Cr.. The value appears strong and on an upward trend. It has increased from 1.06 Cr. (Jun 2025) to 1.35 Cr., marking an increase of 0.29 Cr..
- For Interest, as of Sep 2025, the value is 1.92 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.56 Cr. (Jun 2025) to 1.92 Cr., marking an increase of 0.36 Cr..
- For Depreciation, as of Sep 2025, the value is 5.60 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.38 Cr. (Jun 2025) to 5.60 Cr., marking an increase of 0.22 Cr..
- For Profit before tax, as of Sep 2025, the value is 2.27 Cr.. The value appears to be declining and may need further review. It has decreased from 7.54 Cr. (Jun 2025) to 2.27 Cr., marking a decrease of 5.27 Cr..
- For Tax %, as of Sep 2025, the value is 29.96%. The value appears to be increasing, which may not be favorable. It has increased from 28.38% (Jun 2025) to 29.96%, marking an increase of 1.58%.
- For Net Profit, as of Sep 2025, the value is 1.59 Cr.. The value appears to be declining and may need further review. It has decreased from 5.39 Cr. (Jun 2025) to 1.59 Cr., marking a decrease of 3.80 Cr..
- For EPS in Rs, as of Sep 2025, the value is 1.11. The value appears to be declining and may need further review. It has decreased from 3.75 (Jun 2025) to 1.11, marking a decrease of 2.64.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:30 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21 | 30 | 25 | 140 | 180 | 193 | 205 | 181 | 272 | 331 | 327 | 322 | 325 |
| Expenses | 23 | 29 | 18 | 108 | 128 | 133 | 149 | 157 | 215 | 219 | 269 | 268 | 273 |
| Operating Profit | -3 | 0 | 7 | 32 | 52 | 61 | 56 | 24 | 57 | 112 | 58 | 54 | 52 |
| OPM % | -13% | 1% | 27% | 23% | 29% | 31% | 27% | 13% | 21% | 34% | 18% | 17% | 16% |
| Other Income | 3 | 3 | 0 | 2 | 4 | -15 | -0 | 1 | 6 | 2 | 8 | 6 | 5 |
| Interest | 8 | 7 | 3 | 5 | 4 | 2 | 4 | 3 | 1 | 1 | 1 | 5 | 7 |
| Depreciation | 3 | 4 | 4 | 13 | 12 | 15 | 25 | 20 | 22 | 23 | 22 | 32 | 29 |
| Profit before tax | -10 | -7 | 0 | 16 | 40 | 28 | 27 | 2 | 39 | 91 | 43 | 22 | 21 |
| Tax % | 0% | 0% | 0% | 6% | 36% | 41% | 5% | 479% | 26% | 27% | 30% | 30% | |
| Net Profit | -10 | -7 | 0 | 16 | 25 | 17 | 26 | -8 | 29 | 66 | 30 | 15 | 15 |
| EPS in Rs | 18.42 | 12.07 | 18.36 | -5.72 | 20.40 | 46.69 | 21.08 | 10.60 | 10.41 | ||||
| Dividend Payout % | 0% | 0% | 0% | 11% | 7% | 10% | 7% | 0% | 6% | 3% | 6% | 12% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 30.00% | 100.00% | 56.25% | -32.00% | 52.94% | -130.77% | 462.50% | 127.59% | -54.55% | -50.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 70.00% | -43.75% | -88.25% | 84.94% | -183.71% | 593.27% | -334.91% | -182.13% | 4.55% |
Chemfab Alkalis Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 27% |
| 5 Years: | 10% |
| 3 Years: | 6% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | -12% |
| 3 Years: | -20% |
| TTM: | -33% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 36% |
| 3 Years: | 23% |
| 1 Year: | -26% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | 10% |
| Last Year: | 4% |
Last Updated: September 5, 2025, 1:55 am
Balance Sheet
Last Updated: December 4, 2025, 1:06 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 7 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | -17 | -24 | -17 | 201 | 222 | 237 | 262 | 254 | 284 | 349 | 379 | 393 | 399 |
| Borrowings | 76 | 82 | 66 | 16 | 23 | 34 | 43 | 31 | 9 | 2 | 20 | 84 | 107 |
| Other Liabilities | 10 | 10 | 14 | 44 | 39 | 36 | 30 | 36 | 45 | 48 | 85 | 54 | 85 |
| Total Liabilities | 75 | 73 | 70 | 275 | 298 | 321 | 348 | 335 | 352 | 413 | 498 | 546 | 605 |
| Fixed Assets | 64 | 61 | 57 | 164 | 173 | 194 | 195 | 202 | 194 | 191 | 181 | 249 | 249 |
| CWIP | 0 | 0 | 1 | 11 | 2 | 10 | 35 | 3 | 7 | 14 | 57 | 12 | 61 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 31 | 42 | 110 | 110 | 164 | 149 |
| Other Assets | 10 | 12 | 12 | 99 | 124 | 117 | 110 | 98 | 109 | 98 | 150 | 121 | 146 |
| Total Assets | 75 | 73 | 70 | 275 | 298 | 321 | 348 | 335 | 352 | 413 | 498 | 546 | 605 |
Below is a detailed analysis of the balance sheet data for Chemfab Alkalis Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 14.00 Cr..
- For Reserves, as of Sep 2025, the value is 399.00 Cr.. The value appears strong and on an upward trend. It has increased from 393.00 Cr. (Mar 2025) to 399.00 Cr., marking an increase of 6.00 Cr..
- For Borrowings, as of Sep 2025, the value is 107.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 84.00 Cr. (Mar 2025) to 107.00 Cr., marking an increase of 23.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 85.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 54.00 Cr. (Mar 2025) to 85.00 Cr., marking an increase of 31.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 605.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 546.00 Cr. (Mar 2025) to 605.00 Cr., marking an increase of 59.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 249.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 249.00 Cr..
- For CWIP, as of Sep 2025, the value is 61.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Mar 2025) to 61.00 Cr., marking an increase of 49.00 Cr..
- For Investments, as of Sep 2025, the value is 149.00 Cr.. The value appears to be declining and may need further review. It has decreased from 164.00 Cr. (Mar 2025) to 149.00 Cr., marking a decrease of 15.00 Cr..
- For Other Assets, as of Sep 2025, the value is 146.00 Cr.. The value appears strong and on an upward trend. It has increased from 121.00 Cr. (Mar 2025) to 146.00 Cr., marking an increase of 25.00 Cr..
- For Total Assets, as of Sep 2025, the value is 605.00 Cr.. The value appears strong and on an upward trend. It has increased from 546.00 Cr. (Mar 2025) to 605.00 Cr., marking an increase of 59.00 Cr..
Notably, the Reserves (399.00 Cr.) exceed the Borrowings (107.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -79.00 | -82.00 | -59.00 | 16.00 | 29.00 | 27.00 | 13.00 | -7.00 | 48.00 | 110.00 | 38.00 | -30.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 49 | 42 | 9 | 22 | 35 | 31 | 17 | 31 | 29 | 24 | 24 | 23 |
| Inventory Days | 341 | 320 | 203 | 152 | 84 | 79 | 54 | 89 | 58 | 99 | ||
| Days Payable | 320 | 64 | 546 | 225 | 164 | 156 | 92 | 145 | 101 | 133 | ||
| Cash Conversion Cycle | 70 | 298 | -334 | 22 | 35 | -43 | -63 | -47 | -9 | -32 | -20 | -12 |
| Working Capital Days | -230 | -208 | -329 | -25 | -31 | 10 | -2 | 15 | 5 | 8 | -29 | -16 |
| ROCE % | -4% | -0% | 6% | 15% | 17% | 18% | 11% | 2% | 13% | 28% | 11% | 6% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -4.86 | 18.53 | 45.61 | 20.36 | -5.81 |
| Diluted EPS (Rs.) | -4.84 | 18.34 | 45.14 | 20.36 | -5.81 |
| Cash EPS (Rs.) | 20.46 | 34.21 | 61.71 | 36.06 | 8.60 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 264.55 | 271.92 | 254.72 | 210.84 | 190.09 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 264.55 | 271.92 | 254.72 | 210.84 | 190.09 |
| Revenue From Operations / Share (Rs.) | 232.79 | 230.06 | 233.65 | 192.16 | 128.60 |
| PBDIT / Share (Rs.) | 35.39 | 43.89 | 81.79 | 44.10 | 17.57 |
| PBIT / Share (Rs.) | 10.10 | 28.18 | 65.62 | 28.38 | 3.18 |
| PBT / Share (Rs.) | -0.21 | 27.52 | 63.06 | 27.66 | 1.44 |
| Net Profit / Share (Rs.) | -4.83 | 18.50 | 45.54 | 20.34 | -5.78 |
| NP After MI And SOA / Share (Rs.) | -4.83 | 18.50 | 45.54 | 20.34 | -5.78 |
| PBDIT Margin (%) | 15.20 | 19.07 | 35.00 | 22.95 | 13.65 |
| PBIT Margin (%) | 4.33 | 12.24 | 28.08 | 14.77 | 2.47 |
| PBT Margin (%) | -0.09 | 11.96 | 26.99 | 14.39 | 1.12 |
| Net Profit Margin (%) | -2.07 | 8.04 | 19.49 | 10.58 | -4.49 |
| NP After MI And SOA Margin (%) | -2.07 | 8.04 | 19.49 | 10.58 | -4.49 |
| Return on Networth / Equity (%) | -1.82 | 6.80 | 17.87 | 9.64 | -3.04 |
| Return on Capital Employeed (%) | 3.22 | 9.81 | 25.41 | 13.30 | 1.52 |
| Return On Assets (%) | -1.33 | 5.26 | 15.67 | 8.16 | -2.42 |
| Long Term Debt / Equity (X) | 0.16 | 0.04 | 0.00 | 0.00 | 0.08 |
| Total Debt / Equity (X) | 0.21 | 0.04 | 0.00 | 0.02 | 0.11 |
| Asset Turnover Ratio (%) | 0.65 | 0.71 | 0.86 | 0.79 | 0.52 |
| Current Ratio (X) | 1.65 | 1.09 | 2.71 | 1.82 | 1.83 |
| Quick Ratio (X) | 1.28 | 0.92 | 2.34 | 1.58 | 1.60 |
| Inventory Turnover Ratio (X) | 15.48 | 4.47 | 3.36 | 4.62 | 2.85 |
| Dividend Payout Ratio (NP) (%) | -25.71 | 6.73 | 2.73 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 6.07 | 3.64 | 2.01 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 125.71 | 93.27 | 97.27 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 93.93 | 96.36 | 97.99 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 10.32 | 66.27 | 473.83 | 61.54 | 10.07 |
| Interest Coverage Ratio (Post Tax) (X) | 1.60 | 28.94 | 278.63 | 29.38 | -2.32 |
| Enterprise Value (Cr.) | 1091.47 | 916.08 | 314.58 | 353.32 | 204.65 |
| EV / Net Operating Revenue (X) | 3.26 | 2.80 | 0.94 | 1.30 | 1.13 |
| EV / EBITDA (X) | 21.47 | 14.67 | 2.71 | 5.67 | 8.29 |
| MarketCap / Net Operating Revenue (X) | 3.03 | 2.82 | 0.96 | 1.30 | 0.97 |
| Retention Ratios (%) | 125.71 | 93.26 | 97.26 | 0.00 | 0.00 |
| Price / BV (X) | 2.67 | 2.38 | 0.88 | 1.19 | 0.66 |
| Price / Net Operating Revenue (X) | 3.03 | 2.82 | 0.96 | 1.30 | 0.97 |
| EarningsYield | -0.01 | 0.02 | 0.20 | 0.08 | -0.04 |
After reviewing the key financial ratios for Chemfab Alkalis Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -4.86. This value is below the healthy minimum of 5. It has decreased from 18.53 (Mar 24) to -4.86, marking a decrease of 23.39.
- For Diluted EPS (Rs.), as of Mar 25, the value is -4.84. This value is below the healthy minimum of 5. It has decreased from 18.34 (Mar 24) to -4.84, marking a decrease of 23.18.
- For Cash EPS (Rs.), as of Mar 25, the value is 20.46. This value is within the healthy range. It has decreased from 34.21 (Mar 24) to 20.46, marking a decrease of 13.75.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 264.55. It has decreased from 271.92 (Mar 24) to 264.55, marking a decrease of 7.37.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 264.55. It has decreased from 271.92 (Mar 24) to 264.55, marking a decrease of 7.37.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 232.79. It has increased from 230.06 (Mar 24) to 232.79, marking an increase of 2.73.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 35.39. This value is within the healthy range. It has decreased from 43.89 (Mar 24) to 35.39, marking a decrease of 8.50.
- For PBIT / Share (Rs.), as of Mar 25, the value is 10.10. This value is within the healthy range. It has decreased from 28.18 (Mar 24) to 10.10, marking a decrease of 18.08.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.21. This value is below the healthy minimum of 0. It has decreased from 27.52 (Mar 24) to -0.21, marking a decrease of 27.73.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -4.83. This value is below the healthy minimum of 2. It has decreased from 18.50 (Mar 24) to -4.83, marking a decrease of 23.33.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -4.83. This value is below the healthy minimum of 2. It has decreased from 18.50 (Mar 24) to -4.83, marking a decrease of 23.33.
- For PBDIT Margin (%), as of Mar 25, the value is 15.20. This value is within the healthy range. It has decreased from 19.07 (Mar 24) to 15.20, marking a decrease of 3.87.
- For PBIT Margin (%), as of Mar 25, the value is 4.33. This value is below the healthy minimum of 10. It has decreased from 12.24 (Mar 24) to 4.33, marking a decrease of 7.91.
- For PBT Margin (%), as of Mar 25, the value is -0.09. This value is below the healthy minimum of 10. It has decreased from 11.96 (Mar 24) to -0.09, marking a decrease of 12.05.
- For Net Profit Margin (%), as of Mar 25, the value is -2.07. This value is below the healthy minimum of 5. It has decreased from 8.04 (Mar 24) to -2.07, marking a decrease of 10.11.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -2.07. This value is below the healthy minimum of 8. It has decreased from 8.04 (Mar 24) to -2.07, marking a decrease of 10.11.
- For Return on Networth / Equity (%), as of Mar 25, the value is -1.82. This value is below the healthy minimum of 15. It has decreased from 6.80 (Mar 24) to -1.82, marking a decrease of 8.62.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.22. This value is below the healthy minimum of 10. It has decreased from 9.81 (Mar 24) to 3.22, marking a decrease of 6.59.
- For Return On Assets (%), as of Mar 25, the value is -1.33. This value is below the healthy minimum of 5. It has decreased from 5.26 (Mar 24) to -1.33, marking a decrease of 6.59.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.16. This value is below the healthy minimum of 0.2. It has increased from 0.04 (Mar 24) to 0.16, marking an increase of 0.12.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.21. This value is within the healthy range. It has increased from 0.04 (Mar 24) to 0.21, marking an increase of 0.17.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.65. It has decreased from 0.71 (Mar 24) to 0.65, marking a decrease of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 1.65. This value is within the healthy range. It has increased from 1.09 (Mar 24) to 1.65, marking an increase of 0.56.
- For Quick Ratio (X), as of Mar 25, the value is 1.28. This value is within the healthy range. It has increased from 0.92 (Mar 24) to 1.28, marking an increase of 0.36.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 15.48. This value exceeds the healthy maximum of 8. It has increased from 4.47 (Mar 24) to 15.48, marking an increase of 11.01.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is -25.71. This value is below the healthy minimum of 20. It has decreased from 6.73 (Mar 24) to -25.71, marking a decrease of 32.44.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.07. This value is below the healthy minimum of 20. It has increased from 3.64 (Mar 24) to 6.07, marking an increase of 2.43.
- For Earning Retention Ratio (%), as of Mar 25, the value is 125.71. This value exceeds the healthy maximum of 70. It has increased from 93.27 (Mar 24) to 125.71, marking an increase of 32.44.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.93. This value exceeds the healthy maximum of 70. It has decreased from 96.36 (Mar 24) to 93.93, marking a decrease of 2.43.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 10.32. This value is within the healthy range. It has decreased from 66.27 (Mar 24) to 10.32, marking a decrease of 55.95.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.60. This value is below the healthy minimum of 3. It has decreased from 28.94 (Mar 24) to 1.60, marking a decrease of 27.34.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,091.47. It has increased from 916.08 (Mar 24) to 1,091.47, marking an increase of 175.39.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.26. This value exceeds the healthy maximum of 3. It has increased from 2.80 (Mar 24) to 3.26, marking an increase of 0.46.
- For EV / EBITDA (X), as of Mar 25, the value is 21.47. This value exceeds the healthy maximum of 15. It has increased from 14.67 (Mar 24) to 21.47, marking an increase of 6.80.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.03. This value exceeds the healthy maximum of 3. It has increased from 2.82 (Mar 24) to 3.03, marking an increase of 0.21.
- For Retention Ratios (%), as of Mar 25, the value is 125.71. This value exceeds the healthy maximum of 70. It has increased from 93.26 (Mar 24) to 125.71, marking an increase of 32.45.
- For Price / BV (X), as of Mar 25, the value is 2.67. This value is within the healthy range. It has increased from 2.38 (Mar 24) to 2.67, marking an increase of 0.29.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.03. This value exceeds the healthy maximum of 3. It has increased from 2.82 (Mar 24) to 3.03, marking an increase of 0.21.
- For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to -0.01, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Chemfab Alkalis Ltd:
- Net Profit Margin: -2.07%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.22% (Industry Average ROCE: 7.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -1.82% (Industry Average ROE: 8.14%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.6
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.28
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 37.7 (Industry average Stock P/E: 5)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.21
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -2.07%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Inorganic - Caustic Soda/Soda Ash | Team House, GST Salai, Chennai (Madras) Tamil Nadu 600048 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Suresh Krishnamurthi Rao | Chairman & Non-Exe.Director |
| Mr. C S Ramesh | Non Executive Director |
| Mr. R Mahendran | Non Executive Director |
| Mr. Nitin S Cowlagi | Non Executive Director |
| Mrs. Sujatha Jayarajan | Independent Director |
| Mr. A Janakiraman | Independent Director |
| Mrs. Drushti Desai | Independent Director |
| Mr. Satish Narain Jajoo | Independent Director |
FAQ
What is the intrinsic value of Chemfab Alkalis Ltd?
Chemfab Alkalis Ltd's intrinsic value (as of 24 January 2026) is ₹281.06 which is 28.30% lower the current market price of ₹392.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹563 Cr. market cap, FY2025-2026 high/low of ₹1,053/374, reserves of ₹399 Cr, and liabilities of ₹605 Cr.
What is the Market Cap of Chemfab Alkalis Ltd?
The Market Cap of Chemfab Alkalis Ltd is 563 Cr..
What is the current Stock Price of Chemfab Alkalis Ltd as on 24 January 2026?
The current stock price of Chemfab Alkalis Ltd as on 24 January 2026 is ₹392.
What is the High / Low of Chemfab Alkalis Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Chemfab Alkalis Ltd stocks is ₹1,053/374.
What is the Stock P/E of Chemfab Alkalis Ltd?
The Stock P/E of Chemfab Alkalis Ltd is 37.7.
What is the Book Value of Chemfab Alkalis Ltd?
The Book Value of Chemfab Alkalis Ltd is 288.
What is the Dividend Yield of Chemfab Alkalis Ltd?
The Dividend Yield of Chemfab Alkalis Ltd is 0.32 %.
What is the ROCE of Chemfab Alkalis Ltd?
The ROCE of Chemfab Alkalis Ltd is 5.89 %.
What is the ROE of Chemfab Alkalis Ltd?
The ROE of Chemfab Alkalis Ltd is 3.69 %.
What is the Face Value of Chemfab Alkalis Ltd?
The Face Value of Chemfab Alkalis Ltd is 10.0.